The U.S. Food and Drug Administration announced it has approved Linzess capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation. Linzess is the first treatment approved for IBS-C in pediatric patients, the FDA noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD: